Novartis AG (NVS) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medic...
Novartis AG (NVS) currently trades at a P/E ratio of 20.47 (historical range: 7.02–33.14, median: 18.76), placing it at the 61th percentile — above its historical average, P/S ratio of 5.05 (range: 3.82–5.82, 74th percentile — above its historical average), EV/EBITDA of 17.24 (range: 13.57–26.46, 21th percentile).
Novartis AG trades near its historical valuation range, with most metrics close to their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 20.47 | 18.76 | 61th | above its historical average |
| P/S Ratio | 5.05 | 4.70 | 74th | above its historical average |
| EV/EBITDA | 17.24 | 18.66 | 21th | below its historical average |
| FCF Yield | 5.86% | 6.83% | 12th | expensive relative to its history |
Novartis AG (NVS) Valuation & P/E History
Novartis AG (NVS) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry currently trading at $148.40 with a market capitalization of $282.1 billion. This page provides historical valuation analysis for NVS based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 20.47 is above the historical median of 18.76, placing NVS at the 61th percentile of its valuation range. The P/S ratio of 5.05 compares to a median of 4.70.
NVS Valuation Metrics & Historical Range
The valuation table above shows Novartis AG's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether NVS is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests NVS is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Novartis AG.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is NVS Overvalued or Undervalued?
Novartis AG trades near its historical valuation range, with most metrics close to their median levels. The overall valuation percentile of 52 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive NVS is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full NVS analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.NVS trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.